Cytokinetics reports additional Phase III data for suspended ALS candidate

Cytokinetics Inc. (NASDAQ:CYTK) reported additional data from the Phase III VITALITY-ALS trial in 744 patients with amyotrophic lateral sclerosis (ALS) showing that tirasemtiv reduced mean percent predicted slow vital capacity (SVC) from baseline to week 24, the primary endpoint, by 13.4 percentage points vs. 14.4 percentage points for placebo (p=0.5552). Data were presented at the International ALS/MND Symposium in Boston in December. Tirasemtiv is a fast skeletal muscle troponin activator...